Get the Stockscreener App
36.01
0.29%
0.09
Royalty Pharma Plc stock is traded at $36.01, with a volume of 538.93K.
It is up +0.29% in the last 24 hours and up +1.22% over the past month.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
See More
Previous Close:
$35.92
Open:
$35.96
24h Volume:
538.93K
Relative Volume:
0.15
Market Cap:
$15.57B
Revenue:
$2.31B
Net Income/Loss:
$1.66B
P/E Ratio:
15.66
EPS:
2.3
Net Cash Flow:
$827.02M
1W Performance:
+0.46%
1M Performance:
+1.22%
6M Performance:
+10.54%
1Y Performance:
+31.05%
1-Day Range:
$35.79
$36.22
1-Week Range:
$35.79
$36.85
52-Week Range:
$24.05
$38.00
Royalty Pharma Plc Stock (RPRX) Company Profile
Name
Royalty Pharma Plc
Sector
Industry
Phone
(212) 883-0200
Address
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
36.02 | 15.71B | 2.31B | 1.66B | 827.02M | 2.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
393.25 | 100.71B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
575.57 | 61.52B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
459.06 | 58.84B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
651.91 | 40.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
315.12 | 38.20B | 3.81B | -644.79M | -669.77M | -6.24 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-16-25 | Initiated | Morgan Stanley | Overweight |
| Jun-03-24 | Downgrade | UBS | Buy → Neutral |
| Jun-14-22 | Resumed | UBS | Buy |
| May-13-22 | Initiated | Scotiabank | Sector Outperform |
| Apr-27-22 | Initiated | Goldman | Buy |
| Apr-14-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Oct-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Jul-30-21 | Initiated | Tigress Financial | Buy |
| Nov-09-20 | Upgrade | UBS | Neutral → Buy |
| Jul-14-20 | Initiated | Evercore ISI | In-line |
| Jul-13-20 | Initiated | BofA Securities | Buy |
| Jul-13-20 | Initiated | Citigroup | Neutral |
| Jul-13-20 | Initiated | Cowen | Outperform |
| Jul-13-20 | Initiated | Goldman | Neutral |
| Jul-13-20 | Initiated | JP Morgan | Neutral |
| Jul-13-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-13-20 | Initiated | SunTrust | Buy |
| Jul-13-20 | Initiated | UBS | Neutral |
View All
Royalty Pharma Plc Stock (RPRX) Latest News
Gulf International Bank UK Ltd Has $699,000 Stock Holdings in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Russell Investments Group Ltd. Sells 262,034 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma (RPRX) Q2 Receipts Up 20% - AOL.com
Royalty Pharma plc Price Targets Raised After Rebound2025 Risk Factors & High Return Stock Watch Alerts - newsimpact.co.kr
Citigroup Inc. Has $10.39 Million Stake in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Charles Schwab Investment Management Inc. Sells 9,097 Shares of Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Virtu Financial LLC Increases Position in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Royalty Pharma PLC (NASDAQ:RPRX) Stock Position Reduced by Deutsche Bank AG - MarketBeat
Wealthedge Investment Advisors LLC Takes Position in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Brandywine Global Investment Management LLC Decreases Stock Position in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
22,092 Shares in Royalty Pharma PLC (NASDAQ:RPRX) Acquired by Cookson Peirce & Co. Inc. - MarketBeat
Swiss National Bank Has $33.16 Million Holdings in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Royalty Pharma PLC (NASDAQ:RPRX) Stake Reduced by Forsta AP Fonden - MarketBeat
Mitsubishi UFJ Asset Management Co. Ltd. Buys 55,400 Shares of Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
OneAscent Investment Solutions LLC Makes New $352,000 Investment in Royalty Pharma PLC $RPRX - MarketBeat
Vanguard Group Inc. Has $1.14 Billion Holdings in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Royalty Pharma plc Approaches Psychological Resistance LevelPortfolio Risk Report & Accurate Intraday Trade Tips - classian.co.kr
Is Royalty Pharma plc vulnerable to short sellersWeekly Investment Report & Weekly Top Stock Performers List - classian.co.kr
Earnings Chart Overlay Points to Royalty Pharma plc UpsideJuly 2025 Technicals & High Yield Stock Recommendations - beatles.ru
Can Royalty Pharma plc expand its profit margins2025 Risk Factors & Daily Risk Controlled Trade Plans - thegnnews.com
Koss Olinger Consulting LLC Has $989,000 Stock Holdings in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Henry Fernandez Steps Down from Royalty Pharma’s Board of Directors - citybiz
Royalty Pharma lead independent director Fernandez steps down - Investing.com
Royalty Pharma lead independent director Fernandez steps down By Investing.com - Investing.com Australia
Henry Fernandez Steps Down from Royalty Pharma's Board of Directors - The Manila Times
Cary Street Partners Financial LLC Buys Shares of 19,580 Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Henry Fernandez steps down from Royalty Pharma board - StreetInsider
Royalty Pharma's Lead Independent Director Exits Following Successful Post-IPO Growth Period - Stock Titan
Royalty Pharma (NASDAQ:RPRX) Raised to Buy at Wall Street Zen - MarketBeat
Ex-Dividend Reminder: Eli Lilly, Teleflex and Royalty Pharma - Nasdaq
5 Insightful Analyst Questions From Royalty Pharma’s Q2 Earnings Call - Yahoo Finance
Is Royalty Pharma plc a potential multi baggerGlobal Markets & Fast Gaining Stock Reports - kangso.co.kr
Morgan Stanley Maintains a Buy Rating on Royalty Pharma Plc (RPRX) With a $55 PT - Insider Monkey
RPRX Q2 Deep Dive: Margins Compress Despite Solid Royalty Growth and Strategic Investments - Yahoo Finance
Royalty Pharma Director Norden Gregory Sells 33,500 Shares at $36.23 on 8/11/2025 - AInvest
CenterBook Partners LP Sells 41,728 Shares of Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Royalty Pharma Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Reflecting On Branded Pharmaceuticals Stocks’ Q2 Earnings: Royalty Pharma (NASDAQ:RPRX) - Yahoo Finance
Royalty Pharma raises 2025 portfolio receipts guidance to $3.05B-$3.15B as integrated company advances biotech funding model - MSN
Did Rising Costs and Lower Margins Just Shift Royalty Pharma's (RPRX) Investment Narrative? - simplywall.st
Royalty Pharma Plc Stock (RPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.39%
3.96%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):